
Global Immunodiagnostics Market Report and Forecast 2024-2032
Description
Global Immunodiagnostics Market Report and Forecast 2024-2032
Global Immunodiagnostics Market Report and Forecast 2024-2032
The global immunodiagnostics market was valued at USD 16.09 billion in 2023. It is expected to grow at a CAGR of 6.10% between 2024-2032 and attain a value of 27.42 billion by 2032. The market is driven by increasing geriatric population and use of immunodiagnostics in rapid testing across the globe.
Global Immunodiagnostics Market Analysis
The global immunodiagnostics market has experienced substantial growth over the past few years, driven by advancements in diagnostic technologies and the increasing prevalence of chronic diseases. Immunodiagnostics involves the use of antigen-antibody reactions for the diagnosis of diseases. It encompasses a wide range of tests, including enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and rapid tests, utilised for detecting infections, monitoring disease progression, and evaluating treatment efficacy.
Market Drivers
The primary drivers of the global immunodiagnostics market include:
- Increasing Prevalence of Chronic and Infectious Diseases: The rising incidence of diseases such as cancer, cardiovascular diseases, diabetes, and infectious diseases like HIV and hepatitis is propelling the demand for immunodiagnostic tests. Early and accurate diagnosis is crucial for effective disease management and treatment.
- Technological Advancements: Innovations in immunodiagnostic technologies, including the development of high-throughput assays, automated systems, and point-of-care testing, have significantly improved the accuracy, speed, and convenience of diagnostic procedures. These advancements are enhancing the adoption of immunodiagnostic tests in clinical settings.
- Ageing Population: The growing geriatric population is more susceptible to various chronic and infectious diseases, driving the demand for immunodiagnostic tests. The need for regular health check-ups and monitoring in the elderly population further boosts market growth.
- Increased Healthcare Expenditure: Rising healthcare spending by governments and individuals, particularly in emerging economies, is leading to improved access to diagnostic services. This trend is contributing to the expansion of the immunodiagnostics market.
Despite the promising growth, the immunodiagnostics market faces several challenges:
- High Cost of Diagnostic Tests: The cost of advanced immunodiagnostic tests can be prohibitive, particularly in low- and middle-income countries. This limits the widespread adoption of these tests, especially in resource-limited settings.
- Regulatory Hurdles: Stringent regulatory requirements for the approval of diagnostic tests can delay the introduction of new products to the market. Compliance with varying regulatory standards across different regions adds to the complexity for manufacturers.
- Lack of Skilled Professionals: The shortage of trained healthcare professionals capable of performing and interpreting immunodiagnostic tests is a significant barrier. This issue is more pronounced in rural and underserved areas.
- Sample Quality and Variability: The accuracy of immunodiagnostic tests can be affected by the quality and variability of samples. Inconsistent sample handling and preparation can lead to unreliable results, impacting the credibility of diagnostic tests.
The global immunodiagnostics market presents several future opportunities for growth:
- Emerging Markets: Expanding healthcare infrastructure and increasing healthcare awareness in emerging economies offer significant growth potential for the immunodiagnostics market. Companies are increasingly focusing on these regions to tap into the unmet diagnostic needs.
- Personalised Medicine: The growing trend towards personalised medicine, which tailors treatment based on individual patient profiles, is driving the demand for precise and specific diagnostic tests. Immunodiagnostics plays a crucial role in the development of personalised therapeutic strategies.
- Point-of-Care Testing: The shift towards point-of-care testing, which allows for rapid and convenient diagnosis at or near the site of patient care, is gaining momentum. Innovations in point-of-care immunodiagnostic devices are expected to revolutionise the market by improving accessibility and reducing turnaround times.
- Integration of Artificial Intelligence (AI): The integration of AI and machine learning technologies in immunodiagnostics is enhancing the accuracy and efficiency of diagnostic procedures. AI-driven data analysis and interpretation can provide deeper insights into disease patterns and improve diagnostic outcomes.
- Collaborations and Partnerships: Strategic collaborations between diagnostic companies, research institutions, and healthcare providers are fostering innovation and expanding the reach of immunodiagnostic tests. These partnerships are facilitating the development of novel diagnostic solutions and improving market penetration.
The global immunodiagnostics market, a crucial segment of the broader in-vitro diagnostics (IVD) industry, encompasses a variety of diagnostic tests that leverage antigen-antibody reactions for detecting and monitoring diseases. With applications ranging from infectious disease detection to cancer diagnostics and autoimmune disease monitoring, the market has witnessed robust growth driven by technological advancements and rising healthcare demands.
- Rise of Point-of-Care Testing (POCT): Point-of-care testing (POCT) is revolutionising the immunodiagnostics market by enabling rapid and on-site diagnosis. This trend is particularly notable in remote and underserved regions, where access to centralised laboratories is limited. POCT devices are becoming more sophisticated, offering high accuracy and faster results, which enhances patient management and treatment outcomes.
- Integration of Artificial Intelligence (AI) and Machine Learning (ML): The integration of AI and ML technologies in immunodiagnostics is significantly improving the accuracy and efficiency of diagnostic tests. AI algorithms can analyse complex data sets and identify patterns that may be missed by human analysis. This advancement is aiding in the early detection of diseases, personalised treatment plans, and overall better healthcare outcomes.
- Increasing Adoption of Automated Systems: Personalised medicine, which tailors treatment to individual patient characteristics, is driving demand for precise immunodiagnostic tests. These tests provide detailed insights into a patient's immune response and genetic profile, allowing for more targeted and effective treatments. The growth of personalised medicine is expected to continue bolstering the immunodiagnostics market.
- Expansion in Emerging Markets: Emerging markets, particularly in Asia-Pacific and Latin America, are experiencing rapid growth in the immunodiagnostics sector. Improving healthcare infrastructure, rising disposable incomes, and increasing awareness about early disease detection are contributing to this trend. Companies are investing in these regions to tap into the burgeoning demand for diagnostic services.
- Focus on Infectious Disease Diagnostics: The COVID-19 pandemic has underscored the importance of robust diagnostic capabilities for infectious diseases. There is a heightened focus on developing and improving immunodiagnostic tests for a wide range of infectious diseases, including viral, bacterial, and parasitic infections. This trend is likely to persist as the world remains vigilant about potential future pandemics.
- Advancements in Biomarker Discovery: The discovery of new biomarkers is enhancing the specificity and sensitivity of immunodiagnostic tests. Advances in genomics and proteomics are facilitating the identification of novel biomarkers, which can be used for early detection, prognosis, and monitoring of various diseases. This trend is expanding the scope and application of immunodiagnostics in clinical practice.
- Regulatory Approvals and Reimbursement Policies: Regulatory approvals and favourable reimbursement policies are critical trends shaping the immunodiagnostics market. Streamlined regulatory pathways and supportive reimbursement frameworks are encouraging the development and adoption of new diagnostic tests. Governments and healthcare payers are recognising the value of early and accurate diagnostics in improving patient outcomes and reducing overall healthcare costs.
- Environmental and Ethical Considerations: Sustainability and ethical considerations are becoming increasingly important in the immunodiagnostics market. Companies are focusing on developing eco-friendly diagnostic kits and reducing the environmental impact of their operations. Additionally, ethical considerations, such as ensuring equitable access to diagnostics, are gaining prominence, influencing market strategies and policies.
Global Immunodiagnostics Market Segmentation
Market Breakup by Product Type
- Reagents and Kits
- Consumables
- Instruments
- Software
- Service
Market Breakup by Technology
- Chemiluminescence Immunoassay
- Radioimmunoassay
- Enzyme-Linked Immunosorbent Assay
- Fluorescent Immunoassay
- Rapid Test
- Others
Market Breakup by Application
- Infectious Diseases
- Drug Monitoring
- Oncology and Endocrinology
- Bone and Mineral Diseases
- Cardiac Biomarkers
- Autoimmune Diseases
- Others
Market Breakup by End User
- Hospitals
- Clinical laboratories
- Academic and Research Centres
- Pharmaceutical and Biotechnology Industry
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Immunodiagnostics Market Competitive Landscape
The global immunodiagnostics market features a competitive landscape dominated by key players such as Abbott Laboratories, ARKRAY, Inc., DiaSorin S.p.A., Biotest AG, Immunodiagnostic Systems Holdings plc, F. Hoffmann-La Roche Ltd, Siemens AG, Sysmex Corporation, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., PerkinElmer Inc., and Shenzhen Mindray Bio-Medical Electronics Co Ltd. Common market activities include mergers and acquisitions to expand market reach and capabilities, extensive research initiatives to innovate and improve diagnostic technologies, frequent product introductions to address evolving healthcare needs, and strategic partnerships to enhance market penetration and collaborative development. These activities collectively drive competition and growth in the immunodiagnostics market.
Key Questions Answered in the Report
- What is the current and future performance of the immunodiagnostics market?
- What are the main challenges facing the immunodiagnostics market?
- What are the key drivers of the immunodiagnostics market?
- What emerging trends are shaping the future of the immunodiagnostics market?
- How is point-of-care testing revolutionising the immunodiagnostics market and improving accessibility?
- How do strategic collaborations enhance innovation and market penetration in immunodiagnostics?
- How are new biomarker discoveries advancing the specificity and sensitivity of immunodiagnostic tests?
- Who are the key players in the competitive landscape of the global immunodiagnostics market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global immunodiagnostics market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the immunodiagnostics market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global immunodiagnostics industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Immunodiagnostics Market Overview
- 3.1 Global Immunodiagnostics Market Historical Value (2017-2023)
- 3.2 Global Immunodiagnostics Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Immunodiagnostics Market Landscape*
- 5.1 Global Immunodiagnostics: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Immunodiagnostics: Product Landscape
- 5.2.1 Analysis by Product Type
- 5.2.2 Analysis by Application
- 6 Global Immunodiagnostics Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Immunodiagnostics Market Segmentation (2017-2032)
- 7.1 Global Immunodiagnostics Market (2017-2032) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Reagents and Kits
- 7.1.3 Consumables
- 7.1.4 Instruments
- 7.1.5 Software
- 7.1.6 Service
- 7.2 Global Immunodiagnostics Market (2017-2032) by Technology
- 7.2.1 Market Overview
- 7.2.2 Chemiluminescence Immunoassay
- 7.2.3 Radioimmunoassay
- 7.2.4 Enzyme-Linked Immunosorbent Assay
- 7.2.5 Fluorescent Immunoassay
- 7.2.6 Rapid Test
- 7.2.7 Others
- 7.3 Global Immunodiagnostics Market (2017-2032) by Application
- 7.3.1 Market Overview
- 7.3.2 Infectious Diseases
- 7.3.3 Drug Monitoring
- 7.3.4 Oncology and Endocrinology
- 7.3.5 Bone and Mineral Diseases
- 7.3.6 Cardiac Biomarkers
- 7.3.7 Autoimmune Diseases
- 7.3.8 Others
- 7.4 Global Immunodiagnostics Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Hospitals
- 7.4.3 Clinical laboratories
- 7.4.4 Academic and Research Centres
- 7.4.5 Pharmaceutical and Biotechnology Industry
- 7.4.6 Others
- 7.5 Global Immunodiagnostics Market (2017-2032) by Region
- 7.5.1 Market Overview
- 7.5.2 North America
- 7.5.3 Europe
- 7.5.4 Asia Pacific
- 7.5.5 Latin America
- 7.5.6 Middle East and Africa
- 8 North America Immunodiagnostics Market (2017-2032)
- 8.1 North America Immunodiagnostics Market (2017-2032) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Reagents and Kits
- 8.1.3 Consumables
- 8.1.4 Instruments
- 8.1.5 Software
- 8.1.6 Service
- 8.2 North America Immunodiagnostics Market (2017-2032) by Technology
- 8.2.1 Market Overview
- 8.2.2 Chemiluminescence Immunoassay
- 8.2.3 Radioimmunoassay
- 8.2.4 Enzyme-Linked Immunosorbent Assay
- 8.2.5 Fluorescent Immunoassay
- 8.2.6 Rapid Test
- 8.2.7 Others
- 8.3 North America Immunodiagnostics Market (2017-2032) by Application
- 8.3.1 Market Overview
- 8.3.2 Infectious Diseases
- 8.3.3 Drug Monitoring
- 8.3.4 Oncology and Endocrinology
- 8.3.5 Bone and Mineral Diseases
- 8.3.6 Cardiac Biomarkers
- 8.3.7 Autoimmune Diseases
- 8.3.8 Others
- 8.4 North America Immunodiagnostics Market (2017-2032) by End User
- 8.4.1 Hospitals
- 8.4.2 Clinical laboratories
- 8.4.3 Academic and Research Centres
- 8.4.4 Pharmaceutical and Biotechnology Industry
- 8.4.5 Others
- 8.5 North America Immunodiagnostics Market (2017-2032) by Country
- 8.5.1 United States of America
- 8.5.2 Canada
- 9 Europe Immunodiagnostics Market (2017-2032)
- 9.1 Europe Immunodiagnostics Market (2017-2032) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Reagents and Kits
- 9.1.3 Consumables
- 9.1.4 Instruments
- 9.1.5 Software
- 9.1.6 Service
- 9.2 Europe Immunodiagnostics Market (2017-2032) by Technology
- 9.2.1 Market Overview
- 9.2.2 Chemiluminescence Immunoassay
- 9.2.3 Radioimmunoassay
- 9.2.4 Enzyme-Linked Immunosorbent Assay
- 9.2.5 Fluorescent Immunoassay
- 9.2.6 Rapid Test
- 9.2.7 Others
- 9.3 Europe Immunodiagnostics Market (2017-2032) by Application
- 9.3.1 Market Overview
- 9.3.2 Infectious Diseases
- 9.3.3 Drug Monitoring
- 9.3.4 Oncology and Endocrinology
- 9.3.5 Bone and Mineral Diseases
- 9.3.6 Cardiac Biomarkers
- 9.3.7 Autoimmune Diseases
- 9.3.8 Others
- 9.4 Europe Immunodiagnostics Market (2017-2032) by End User
- 9.4.1 Hospitals
- 9.4.2 Clinical laboratories
- 9.4.3 Academic and Research Centres
- 9.4.4 Pharmaceutical and Biotechnology Industry
- 9.4.5 Others
- 9.5 Europe Immunodiagnostics Market (2017-2032) by Country
- 9.5.1 United Kingdom
- 9.5.2 Germany
- 9.5.3 France
- 9.5.4 Italy
- 9.5.5 Others
- 10 Asia Pacific Immunodiagnostics Market (2017-2032)
- 10.1 Asia Pacific Immunodiagnostics Market (2017-2032) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Reagents and Kits
- 10.1.3 Consumables
- 10.1.4 Instruments
- 10.1.5 Software
- 10.1.6 Service
- 10.2 Asia Pacific Immunodiagnostics Market (2017-2032) by Technology
- 10.2.1 Market Overview
- 10.2.2 Chemiluminescence Immunoassay
- 10.2.3 Radioimmunoassay
- 10.2.4 Enzyme-Linked Immunosorbent Assay
- 10.2.5 Fluorescent Immunoassay
- 10.2.6 Rapid Test
- 10.2.7 Others
- 10.3 Asia Pacific Immunodiagnostics Market (2017-2032) by Application
- 10.3.1 Market Overview
- 10.3.2 Infectious Diseases
- 10.3.3 Drug Monitoring
- 10.3.4 Oncology and Endocrinology
- 10.3.5 Bone and Mineral Diseases
- 10.3.6 Cardiac Biomarkers
- 10.3.7 Autoimmune Diseases
- 10.3.8 Others
- 10.4 Asia Pacific Immunodiagnostics Market (2017-2032) by End User
- 10.4.1 Hospitals
- 10.4.2 Clinical laboratories
- 10.4.3 Academic and Research Centres
- 10.4.4 Pharmaceutical and Biotechnology Industry
- 10.4.5 Others
- 10.5 Asia Pacific Immunodiagnostics Market (2017-2032) by Country
- 10.5.1 China
- 10.5.2 Japan
- 10.5.3 India
- 10.5.4 ASEAN
- 10.5.5 Australia
- 10.5.6 Others
- 11 Latin America Immunodiagnostics Market (2017-2032)
- 11.1 Latin America Immunodiagnostics Market (2017-2032) by Product Type
- 11.1.1 Market Overview
- 11.1.2 Reagents and Kits
- 11.1.3 Consumables
- 11.1.4 Instruments
- 11.1.5 Software
- 11.1.6 Service
- 11.2 Latin America Immunodiagnostics Market (2017-2032) by Technology
- 11.2.1 Market Overview
- 11.2.2 Chemiluminescence Immunoassay
- 11.2.3 Radioimmunoassay
- 11.2.4 Enzyme-Linked Immunosorbent Assay
- 11.2.5 Fluorescent Immunoassay
- 11.2.6 Rapid Test
- 11.2.7 Others
- 11.3 Latin America Immunodiagnostics Market (2017-2032) by Application
- 11.3.1 Market Overview
- 11.3.2 Infectious Diseases
- 11.3.3 Drug Monitoring
- 11.3.4 Oncology and Endocrinology
- 11.3.5 Bone and Mineral Diseases
- 11.3.6 Cardiac Biomarkers
- 11.3.7 Autoimmune Diseases
- 11.3.8 Others
- 11.4 Latin America Immunodiagnostics Market (2017-2032) by End User
- 11.4.1 Hospitals
- 11.4.2 Clinical laboratories
- 11.4.3 Academic and Research Centres
- 11.4.4 Pharmaceutical and Biotechnology Industry
- 11.4.5 Others
- 11.5 Latin America Immunodiagnostics Market (2017-2032) by Country
- 11.5.1 Brazil
- 11.5.2 Argentina
- 11.5.3 Mexico
- 11.5.4 Others
- 12 Middle East and Africa Immunodiagnostics Market (2017-2032)
- 12.1 Middle East and Africa Immunodiagnostics Market (2017-2032) by Product Type
- 12.1.1 Market Overview
- 12.1.2 Reagents and Kits
- 12.1.3 Consumables
- 12.1.4 Instruments
- 12.1.5 Software
- 12.1.6 Service
- 12.2 Middle East and Africa Immunodiagnostics Market (2017-2032) by Technology
- 12.2.1 Market Overview
- 12.2.2 Chemiluminescence Immunoassay
- 12.2.3 Radioimmunoassay
- 12.2.4 Enzyme-Linked Immunosorbent Assay
- 12.2.5 Fluorescent Immunoassay
- 12.2.6 Rapid Test
- 12.2.7 Others
- 12.3 Middle East and Africa Immunodiagnostics Market (2017-2032) by Application
- 12.3.1 Market Overview
- 12.3.2 Infectious Diseases
- 12.3.3 Drug Monitoring
- 12.3.4 Oncology and Endocrinology
- 12.3.5 Bone and Mineral Diseases
- 12.3.6 Cardiac Biomarkers
- 12.3.7 Autoimmune Diseases
- 12.3.8 Others
- 12.4 Middle East and Africa Immunodiagnostics Market (2017-2032) by End User
- 12.4.1 Hospitals
- 12.4.2 Clinical laboratories
- 12.4.3 Academic and Research Centres
- 12.4.4 Pharmaceutical and Biotechnology Industry
- 12.4.5 Others
- 12.5 Middle East and Africa Immunodiagnostics Market (2017-2032) by Country
- 12.5.1 Saudi Arabia
- 12.5.2 United Arab Emirates
- 12.5.3 Nigeria
- 12.5.4 South Africa
- 12.5.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Strategic Initiative
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share Analysis, By Region (Top 5 Companies)
- 16.1.1 Market Share Analysis: Global
- 16.1.2 Market Share Analysis: North America
- 16.1.3 Market Share Analysis: Europe
- 16.1.4 Market Share Analysis: Asia-Pacific
- 16.1.5 Market Share Analysis: Others
- 16.2 Abbott Laboratories
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 ARKRAY, Inc .
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 DiaSorin S.p.A .
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Johnson & Johnson Services, Inc .
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Biotest AG
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Immunodiagnostic Systems Holdings plc
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 F. Hoffmann-La Roche Ltd
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 Siemens AG
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 Sysmex Corporation
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic Reach and Achievements
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Danaher Corporation
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 16.12 Thermo Fisher Scientific Inc .
- 16.12.1 Financial Analysis
- 16.12.2 Product Portfolio
- 16.12.3 Demographic
- 16.12.4 Mergers and Acquisitions
- 16.12.5 Certifications
- 16.13 Bio-Rad Laboratories, Inc .
- 16.13.1 Financial Analysis
- 16.13.2 Product Portfolio
- 16.13.3 Demographic Reach and Achievements
- 16.13.4 Mergers and Acquisitions
- 16.13.5 Certifications
- 16.14 PerkinElmer Inc .
- 16.14.1 Financial Analysis
- 16.14.2 Product Portfolio
- 16.14.3 Demographic Reach and Achievements
- 16.14.4 Mergers and Acquisitions
- 16.14.5 Certifications
- 16.15 Shenzhen Mindray Bio-Medical Electronics Co Ltd .
- 16.15.1 Financial Analysis
- 16.15.2 Product Portfolio
- 16.15.3 Demographic Reach and Achievements
- 16.15.4 Mergers and Acquisitions
- 16.15.5 Certifications
- 17 Immunodiagnostics Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.